{"commentary":{"count":204,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":100,"youtube":61,"podcast":38,"x_video":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05374512\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05374512","nct_id":"NCT05374512","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05374512. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Arm 1: Dato-DXd","label":"Dato-DXd","type":"EXPERIMENTAL"},{"description":"Arm 2:\n\nIf no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI \\> 12 months, paclitaxel or nab-paclitaxel\n\nIf prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin.","label":"Investigator's Choice of Chemotherapy (ICC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":644,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dato-DXd","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Nab-paclitaxel","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Eribulin mesylate","type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"AstraZeneca","official_title":"A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-08-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)"},{"measure":"Overall Survival (OS)","timeFrame":"From randomisation until the date of death due to any cause (approximately 42 months)"}],"references":[{"citation":"Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortes J. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1.","pmid":"37526149","type":"DERIVED"}],"start_date":{"date":"2022-05-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","url":"https://clinicaltrials.gov/study/NCT05374512"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05374512"}